Clene (CLNN) to Post Earnings on Thursday

Clene (NASDAQ:CLNN) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $0.0610 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Clene (NASDAQ:CLNN) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.05). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.05 million. On average, analysts expect Clene to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clene Stock Down 2.3%

Shares of Clene stock opened at $5.16 on Tuesday. The stock has a market cap of $65.94 million, a PE ratio of -1.61 and a beta of 0.96. The business has a fifty day simple moving average of $5.73 and a 200 day simple moving average of $5.66. Clene has a 12 month low of $3.50 and a 12 month high of $13.50.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of Clene in a research report on Monday, May 4th. Weiss Ratings cut Clene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. HC Wainwright restated a “buy” rating and issued a $31.00 price target on shares of Clene in a research note on Monday, May 4th. Finally, Roth Capital reiterated a “buy” rating on shares of Clene in a research note on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $33.25.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CLNN. SymBiosis Capital Partners LLC bought a new stake in shares of Clene in the 4th quarter worth approximately $4,523,000. Scoggin Management LP boosted its stake in shares of Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after purchasing an additional 107,250 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in shares of Clene by 668.6% during the 4th quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after purchasing an additional 99,481 shares during the last quarter. PEAK6 LLC bought a new position in shares of Clene during the 4th quarter valued at $294,000. Finally, State Street Corp raised its position in Clene by 138.4% in the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after purchasing an additional 17,300 shares during the period. Institutional investors own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).